Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: Use of peptide glycomimics

Journal of Neurochemistry

Volumn 113, Issue 2, 2010, Pages 351-362

  Usuki, Seigo ^a   Taguchi, Kyoji ^b   Gu, Yi Hua ^a   Thompson, Stuart A ^a   Yu, Robert K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Campylobacter jejuni; Ganglioside GD3; Guillain Barr syndrome; Lipo oligosaccharide; Molecular mimicry; Phage display peptide

Indexed keywords

ALANYLCYSTEINYLTHREONYLPROLYLTYROSYLALANYLMETHIONYLLEUCYLPROLYLGLYCYLCYSTEINYLLYSINAMIDE; ARGINYLHISTIDYLALANYLTYROSYLARGINYLSERYLMETHIONYLALANYLGLUTAMYLTRYPTOPHANYLGLYCINYLPHENYLALANYLLEUCYLTYROSYLSERINAMIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; GLYCYLLEUCYLALANYLPROLYLPROLYLASPARTYLTYROSYLALANYLGLUTAMYLARGINYLPHENYLALANYLPHENYLALANYLLEUCYLISOLEUCYLSERINAMIDE; LEUCYLALANYLPROLYLVALINYLARGINYLPROLYLARGINYLSERYLGLUTAMYLLEUCYLVALYLPHENYLALANYLLEUCYLSERYLVALINAMIDE; OLIGOSACCHARIDE; PROLYLHISTIDYLPHENYLALANYLASPARTYLSERYLLEUCYLLEUCYLTYROSYLPROLYLCYSTEINYLGLUTAMYLLEUCYLLEUCYLGLYCYLCYSTEINAMIDE; SERYLVALYLALANYLVALYLPROLYLPROLYLPROLYLALANYLASPARTYLASPARTYLPROLINYLSERYLTRYPTOPHANYLARGINYLTYROSINAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; GLYCOBIOLOGY; GUILLAIN BARRE SYNDROME; HISTOPATHOLOGY; MOLECULAR MIMICRY; MOTOR NERVE CONDUCTION; NEURITIS; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; ROTAROD TEST; SENSITIZATION;

ANIMALS; AUTOANTIBODIES; BODY WEIGHT; COCULTURE TECHNIQUES; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DRUG DESIGN; FEMALE; GANGLIOSIDES; LIPOPOLYSACCHARIDES; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR MIMICRY; MOTOR ACTIVITY; MOTOR NEURONS; NEURAL CONDUCTION; NEURITIS; NEUROMUSCULAR JUNCTION; OLIGOSACCHARIDES; PEPTIDES; PERIPHERAL NERVES; RATS; RATS, INBRED LEW; TIME FACTORS;

CAMPYLOBACTER JEJUNI; RATTUS;

EID: 77949755756     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06627.x     Document Type: Article

References (41)

1. Ariga T. Yu R. K. (2005) Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: Review of clinical features and antibody specificities. J. Neurosci. Res. 80, 1 17.
2. Aspinall G. O., McDonald A. G., Raju T. S., Pang H., Mills S. D., Kurjanczyk L. A. Penner J. L. (1992) Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides. J. Bacteriol. 174, 1324 1332.
3. Aspinall G. O., McDonald A. G., Pang H., Kurjanczyk L. A. Penner J. L. (1994) Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 33, 241 249.
4. Buchwald B., Toyka K. V., Zielasek J., Weishaupt A., Schweiger S. Dudel J. (1998) Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann. Neurol. 44, 913 922.
5. Chapman P. B. Houghton A. N. (1991) Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J. Clin. Invest. 88, 186 192.
6. DeLano W. L. 2002. The PyMOL Molecular Graphics System. DeLano Scinetific, Palo Alto, CA, USA. Available at: http://www.pymol.org.
7. Dunham N. W. Miya T. S. (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim) 46, 208 209.
8. Goodyear C. S., O'Hanlon G. M., Plomp J. J. et al. (1999) Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104, 697 708.
9. Guex N. Peitsch M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714 2723.
10. Hahn A. F. (1998) Guillain-Barré syndrome. Lancet 352, 635 641.
11. Hughes R. A. Cornblath D. R. (2005) Guillain-Barré syndrome. Lancet 366, 1653 1666.
12. Hughes R. A. Rees J. H. (1997) Clinical and epidemiologic features of Guillain-Barré syndrome. J. Infect. Dis. 176 (Suppl 2 S92 S98.
13. Hughes R. A., Hadden R. D., Gregson N. A. Smith K. J. (1999) Pathogenesis of Guillain-Barré syndrome. J. Neuroimmunol. 100, 74 97.
14. Jones B. J. Roberts D. J. (1968) The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J. Pharm. Pharmacol. 20, 302 304.
15. Kaida K., Morita D., Kanzaki M., Kamakura K., Motoyoshi K., Hirakawa M. Kusunoki S. (2007) Anti-ganglioside complex antibodies associated with severe disability in GBS. J. Neuroimmunol. 182, 212 218.
16. Kaida K., Ariga T. Yu R. K. (2009) Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders - a review. Glycobiology 19, 676 692.
17. Koga M., Gilbert M., Li J., Koike S., Takahashi M., Furukawa K., Hirata K. Yuki N. (2005) Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 64, 1605 1611.
18. Lozeron P. Adams D. (2007) Monoclonal gammopathy and neuropathy. Curr. Opin. Neurol. 20, 536 541.
19. Morris G. M., Goodsell D. S., Huey R. Olson A. J. (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des. 10, 293 304.
20. Popa I., Ishikawa D., Tanaka M., Ogino K., Portoukalian J. Taki T. (2006) GD3-replica peptides selected from a phage peptide library induce a GD3 ganglioside antibody response. FEBS Lett. 580, 1398 1404.
21. Regina Todeschini A. Hakomori S. I. (2008) Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim. Biophys. Acta 1780, 421 433.
22. Ren S., Scarsdale J. N., Ariga T., Zhang Y., Klein R. A., Hartmann R., Kushi Y., Egge H. Yu R. K. (1992) O-Acetylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. J. Biol. Chem. 267, 12632 12638.
23. Rogers D. C., Campbell C. A., Stretton J. L. Mackay K. B. (1997) Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 28, 2060 2065 discussion 2066.
24. Salloway S., Mermel L. A., Seamans M., Aspinall G. O., Nam Shin J. E., Kurjanczyk L. A. Penner J. L. (1996) Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 64, 2945 2949.
25. Sanner M. F. (1999) Python: a programming language for software integration and development. J. Mol. Graph. Model 17, 57 61.
26. Shoenfeld Y. (2004) The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat. Med. 10, 17 18.
27. Simon-Haldi M., Mantei N., Franke J., Voshol H. Schachner M. (2002) Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope. J. Neurochem. 83, 1380 1388.
28. Svennerholm L. (1964) The gangliosides. J. Lipid Res. 5, 145 155.
29. Taguchi K., Ren J., Utsunomiya I., Aoyagi H., Fujita N., Ariga T., Miyatake T. Yoshino H. (2004) Neurophysiological and immunohistochemical studies on Guillain-Barré syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission. J. Neurol. Sci. 225, 91 98.
30. Usuki S., Sanchez J., Ariga T., Utsunomiya I., Taguchi K., Rivner M. H. Yu R. K. (2005) AIDP and CIDP having specific antibodies to the carbohydrate epitope (-NeuAcalpha2-8NeuAcalpha2-3Galbeta1-4Glc-) of gangliosides. J. Neurol. Sci. 232, 37 44.
31. Usuki S., Thompson S. A., Rivner M. H., Taguchi K., Shibata K., Ariga T. Yu R. K. (2006) Molecular mimicry: sensitization of Lewis rats with Campylobacter jejuni lipopolysaccharides induces formation of antibody toward GD3 ganglioside. J. Neurosci. Res. 83, 274 284.
32. Usuki S., Taguchi K., Thompson S. A., Chapman P. B. Yu R. K. (2009) Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré Syndrome. J. Neurosci. Res. (in press).
33. Willers J., Lucchese A., Kanduc D. Ferrone S. (1999) Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 20, 1021 1026.
34. Yamawaki M., Vasquez A., Ben Younes A., Yoshino H., Kanda T., Ariga T., Baumann N. Yu R. K. (1996) Sensitization of Lewis rats with sulfoglucuronosyl paragloboside: electrophysiological and immunological studies of an animal model of peripheral neuropathy. J. Neurosci. Res. 44, 58 65.
35. Yan X., Evans S. V., Kaminki M. J., Gillies S. D., Reisfeld R. A., Houghton A. N. Chapman P. B. (1996) Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. J. Immunol. 157, 1582 1588.
36. Yu R. K., Bieberich E., Xia T. Zeng G. (2004) Regulation of ganglioside biosynthesis in the nervous system. J. Lipid Res. 45, 783 793.
37. Yu R. K., Usuki S. Ariga T. (2006) Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Infect. Immun. 74, 6517 6527.
38. Yuki N. (2007) Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 35, 691 711.
39. Yuki N., Yoshino H., Sato S. Miyatake T. (1990) Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40, 1900 1902.
40. Yuki N., Taki T., Inagaki F., Kasama T., Takahashi M., Saito K., Handa S. Miyatake T. (1993) A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178, 1771 1775.
41. Yuki N., Susuki K., Koga M. et al. (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl. Acad. Sci. U S A 101, 11404 11409.